



(51) International Patent Classification:

A61K 38/21 (2006.01) C07K 14/555 (2006.01)

(21) International Application Number:

PCT/US2018/055888

(22) International Filing Date:

15 October 2018 (15.10.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/571,900 13 October 2017 (13.10.2017) US

(71) Applicants: **THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS** [US/US]; 2810 Vermont Ave. NE, Washington, DC 20420 (US). **MEIOGEN BIOTECHNOLOGY CORPORATION** [US/US]; 20 Assembly Square Drive, Somerville, MA 02145 (US).

(72) Inventors: **TYOR, William**; 1071 Hedge Rose Ct., Atlanta, GA 30324 (US). **KONERU, Rajeth**; 2770 Cezanne Ln., Cumming, GA 30041 (US). **WARD, Jennifer**; 39 Como Road, Boston, MA 02136 (US). **MAROUN, Leonard**; 2101 North Ursula Street, Apt. 323, Aurora, CO 80045 (US).

(74) Agent: **MARTY, Scott D.** et al.; Ballard Spahr LLP, 999 Peachtree Street, Suite 1000, Atlanta, GA 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(54) Title: COMPOSITIONS AND METHODS OF INTERFERON ALPHA BINDING PROTEINS




FIG. 1A

(57) Abstract: Disclosed are compositions comprising an interferon-alpha binding protein and combined anti-retroviral therapy (cART). In some aspects, the interferon-alpha binding protein is B18R or variants thereof. In some aspects, the compositions further comprise a pharmaceutically acceptable carrier. Disclosed are methods of treating a subject with HIV associated neurodegenerative disorder (HAND) comprising administering a therapeutically effective amount of B18R or variants thereof and cART. Disclosed are methods of reversing behavioral abnormalities in subjects having HAND comprising administering a therapeutically effective amount of B18R or variants thereof.



Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

Compositions and Methods of Interferon Alpha Binding Proteins

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

[0001] This invention was made with government support under 1101BX001506-01A2 awarded by the Department of Veterans Affairs. The government has certain rights in the invention.

BACKGROUND

[0002] HIV associated neurogenerative disorders (HAND) occurs in up to 50% of roughly 35 million people living with HIV, even with combined antiretroviral therapy (cART). New therapeutic approaches are paramount. HAND includes asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder (MND), which comprise most of the HAND disorders in cART treated patients. HIV associated dementia (HAD) is a more important condition in countries where cART is unavailable. According to the Antinori *et al.* criteria ANI and MND require neuropsychological testing. The underlying histopathology of ANI and MND are poorly understood compared to HAD. These factors are highly relevant to the development of HAND animal models because they dictate the need to incorporate behavioral measures. Novel treatments for HAND are currently needed.

BRIEF SUMMARY

[0003] Disclosed are compositions comprising an interferon-alpha (IFN α) binding protein and combined anti-retroviral therapy (cART). In some aspects, the IFN α binding protein is B18R or a variant thereof. In some aspects, the compositions further comprise a pharmaceutically acceptable carrier.

[0004] Disclosed are methods of treating a subject with HAND comprising administering a therapeutically effective amount of B18R or a variant thereof and cART.

[0005] Disclosed are methods of reversing behavioral abnormalities in subjects having HAND comprising administering a therapeutically effective amount of B18R or a variant thereof. Disclosed are methods of reversing behavioral abnormalities in subjects having HAND comprising administering a therapeutically effective amount of B18R or a variant thereof and cART.

[0006] Additional advantages of the disclosed method and compositions will be set forth in part in the description which follows, and in part will be understood from the description, or may be learned by practice of the disclosed method and compositions. The advantages of the disclosed method and compositions will be realized and attained by means of the elements and

combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed.

BRIEF DESCRIPTION OF THE DRAWINGS

[0007] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the disclosed method and compositions and together with the description, serve to explain the principles of the disclosed method and compositions.

[0008] Figures 1A, 1B, and 1C show densitometry values for astrogliosis (A), microgliosis (B) and dendritic arborization (C). * $p < 0.05$

[0009] Figure 2 is a schematic of methods in experiment 2.

[0010] Figures 3A, 3B, 3C, and 3D show identical and novel objects in ORT. A. Day 5 B. Day 6 C. Day 12 D. Day 13

[0011] Figures 4A, 4B, 4C, and 4D are graphs showing the discrimination index for novel object testing (A), Day 5 (B), Day 6 (C) Day 12, (D) Day 13. * $p < 0.05$, ** $p < 0.01$

[0012] Figure 5 is a graph of PSD95 puncta per unit length vs duration of treatment. PSD-95 puncta in vehicle treated and IFN α treated neuronal cultures averaged over 3 separate experiments. PSD-95 puncta were counted by a blinded observer and these numbers were averaged for each experiment. * $p < 0.05$.

[0013] Figure 6 is a representative Western Blot of Arf1 expression from vehicle treated and IFN α treated (300 IU/ml) rat neurons for various times. Representative of 3 experiments. Gapdh=glyceraldehyde 3-phosphate dehydrogenase.

[0014] Figures 7A-7C show GLuR2 (AMPA) immunofluorescent staining of control (A) and IFN α treated (B) DIV14 rat neurons. 100X photomicrographs. Densitometry was taken from 27 random images representative of 2 experiments (C). * $p = 0.0000000000415$.

[0015] Figure 8 shows a schematic depicting the methodology of the ORT with the treatments and tests for each day (day = D). For example, D5 represents day 5 after IC inoculation of human cells.

[0016] Figures 9A-9H show representative images of rat neurons double-stained for PSD-95 (red) and MAP2 (green). (A) sham control neuron (20X magnification). (B&C) selected dendrites from control neuron (A) (100X magnification), (D) representative neuron after 2 hours of treatment with IFN α (20X magnification), (E&F) selected dendrites from IFN α treated neuron (D). (G) representative neuron from 20 minutes sham control group, and (H) a representative neuron, 20 minutes after treatment with IFN α . Threshold was adjusted to accept PSD-95 puncta

brighter than 140 (255 maximum brightness). Pixels above threshold are colored white and counted as PSD-95 positive puncta.

DETAILED DESCRIPTION

[0017] The disclosed method and compositions may be understood more readily by reference to the following detailed description of particular embodiments and the Example included therein and to the Figures and their previous and following description.

[0018] It is to be understood that the disclosed method and compositions are not limited to specific synthetic methods, specific analytical techniques, or to particular reagents unless otherwise specified, and, as such, may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0019] Disclosed are materials, compositions, and components that can be used for, can be used in conjunction with, can be used in preparation for, or are products of the disclosed method and compositions. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. Thus, if a class of molecules A, B, and C are disclosed as well as a class of molecules D, E, and F and an example of a combination molecule, A-D is disclosed, then even if each is not individually recited, each is individually and collectively contemplated. Thus, in this example, each of the combinations A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. Likewise, any subset or combination of these is also specifically contemplated and disclosed. Thus, for example, the sub-group of A-E, B-F, and C-E are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. This concept applies to all aspects of this application including, but not limited to, steps in methods of making and using the disclosed compositions. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment or combination of embodiments of the disclosed methods, and that each such combination is specifically contemplated and should be considered disclosed.

A. Definitions

[0020] It is understood that the disclosed method and compositions are not limited to the

particular methodology, protocols, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

[0021] It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a subject" includes a plurality of such subjects, reference to "the IFN α binding protein" is a reference to one or more IFN α binding proteins and equivalents thereof known to those skilled in the art, and so forth.

[0022] As used herein, the term "therapeutically effective amount" means an amount of a therapeutic, prophylactic, and/or diagnostic agent that is sufficient, when administered to a subject suffering from or susceptible to a disease, disorder, and/or condition, to treat, alleviate, ameliorate, relieve, alleviate symptoms of, prevent, delay onset of, inhibit progression of, reduce severity of, and/or reduce incidence of the disease, disorder, and/or condition.

[0023] As used herein, the term "treating" refers to partially or completely alleviating, ameliorating, relieving, delaying onset of, inhibiting progression of, reducing severity of, and/or reducing incidence of one or more symptoms or features of a particular disease, disorder, and/or condition. Treatment may be administered to a subject who does not exhibit signs of a disease, disorder, and/or condition and/or to a subject who exhibits only early signs of a disease, disorder, and/or condition for the purpose of decreasing the risk of developing pathology associated with the disease, disorder, and/or condition.

[0024] As used herein, the terms "inhibit," "inhibiting," and "inhibition" mean to diminish or decrease an activity, response, condition, disease, or other biological parameter. This can include, but is not limited to, the complete ablation of the activity, response, condition, or disease. This may also include, for example, a 10% inhibition or reduction in the activity, response, condition, or disease as compared to the native or control level. Thus, in an aspect, the inhibition or reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 percent, or any amount of reduction in between as compared to native or control levels. In an aspect, the inhibition or reduction is 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, or 90-100 percent as compared to native or control levels. In an aspect, the inhibition or reduction is 0-25, 25-50, 50-75, or 75-100 percent as compared to native or control levels. Further, the terms, "inhibit" or "inhibiting" mean decreasing tumor cell growth rate from the rate that would occur without treatment and/or causing tumor mass (e.g., cancer) to decrease. Inhibiting also include causing a complete regression of the tumor (e.g., cancer).

[0025] By "pharmaceutically acceptable carrier" is meant a diluent, excipient, or adjuvant which is physiologically acceptable to the subject while retaining the therapeutic properties of the composition with which it is administered. One exemplary pharmaceutically acceptable carrier is physiological saline. Other physiologically acceptable diluents, excipients, carriers, or adjuvants and their formulations are known to one skilled in the art.

[0026] The term "subject" or "patient" refers to any organism to which a composition of this invention may be administered, e.g., for experimental, diagnostic, and/or therapeutic purposes. Typical subjects include animals (e.g., mammals such as non-human primates, and humans; avians; domestic household or farm animals such as cats, dogs, sheep, goats, cattle, horses and pigs; laboratory animals such as mice, rats and guinea pigs) and/or plants. Typically, "subjects" are animals, including mammals such as humans and primates; and the like.

[0027] Subjects having HIV associated neurodegenerative disorder (HAND) refers to people living with HIV have learning and memory problems, which includes three disorders – asymptomatic neurocognitive impairment, mild neurocognitive disorder and HIV associated dementia (HAD).

[0028] As used herein, HAD, the most severe form of HAND, is where the patient's brain dysfunction makes them unable to accomplish everyday functions. HAD patients become increasingly unable to perform even rudimentary types of functions such as talking or walking and eventually death ensues.

[0029] "Optional" or "optionally" means that the subsequently described event, circumstance, or material may or may not occur or be present, and that the description includes instances where the event, circumstance, or material occurs or is present and instances where it does not occur or is not present.

[0030] Ranges may be expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, also specifically contemplated and considered disclosed is the range from the one particular value and/or to the other particular value unless the context specifically indicates otherwise. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another, specifically contemplated embodiment that should be considered disclosed unless the context specifically indicates otherwise. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint unless the context specifically indicates otherwise. Finally, it should be understood that all of the individual values and sub-ranges of values contained within an explicitly disclosed range are also specifically contemplated and should be considered

disclosed unless the context specifically indicates otherwise. The foregoing applies regardless of whether in particular cases some or all of these embodiments are explicitly disclosed.

[0031] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed method and compositions belong. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present method and compositions, the particularly useful methods, devices, and materials are as described. Publications cited herein and the material for which they are cited are hereby specifically incorporated by reference. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such disclosure by virtue of prior invention. No admission is made that any reference constitutes prior art. The discussion of references states what their authors assert, and applicants reserve the right to challenge the accuracy and pertinency of the cited documents. It will be clearly understood that, although a number of publications are referred to herein, such reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art.

[0032] Throughout the description and claims of this specification, the word “comprise” and variations of the word, such as “comprising” and “comprises,” means “including but not limited to,” and is not intended to exclude, for example, other additives, components, integers or steps. In particular, in methods stated as comprising one or more steps or operations it is specifically contemplated that each step comprises what is listed (unless that step includes a limiting term such as “consisting of”), meaning that each step is not intended to exclude, for example, other additives, components, integers or steps that are not listed in the step.

B. Compositions

[0033] Disclosed are compositions comprising an IFN α binding protein and/or combined anti-retroviral therapy (cART). In some aspects, the IFN α binding protein can be virus-derived. In some aspects, the IFN α binding protein can be B18R or a variant thereof. In any of the compositions or methods disclosed throughout, the IFN α binding protein can be B18R or a variant thereof.

[0034] By “B18R” is meant the IFN α inhibitor protein termed B18R. In some aspects, B18R can be the sequence of Genbank # 01019.1; SEQ ID NO:1. The B18R protein is a type I interferon receptor encoded by the B18R gene of the Western Reserve vaccinia virus strain. The 60-65 kD glycoprotein is related to the interleukin-1 receptors and is a member of the immunoglobulin superfamily, unlike other type I IFN-receptors, which belong to the class II

cytokine receptor family. The B18R protein has a high affinity (KD, 174 pM) for human IFN α and, unlike other type I IFN receptors, has broad species specificity, binding to type I interferons of human, mouse, rat, rabbit, pig, and cow. Among viral host response modifiers, the B18R protein is unique in that it exists as a soluble extracellular, as well as a cell surface protein, enabling blockage of both autocrine and paracrine IFN functions. The B18R protein has been shown to inhibit the antiviral potency of IFN α 1, IFN α 2, IFN α -8/1/8, and IFN-omega on human cells. In an aspect, the B18R protein has the sequence set forth in SEQ ID NO:1. In some aspects, B18R can be a homolog of the vaccinia virus produced B18R, such as B18R produced by the Orthopox and related families of viruses. The disclosed B18R proteins and variants thereof have the shared ability to strongly bind to, and inhibit, the IFN α family of cytokines. In an aspect, the B18R variant can have a greater than 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identity or similarity to SEQ ID NO: 1. In an aspect, the B18R variant can be a deletion mutant such as the deletion variant described in U.S. Patent No. 9,861,681 which is hereby incorporated by reference in its entirety for its teaching of a B18R variant.

[0035] SEQ ID NO:1 consists of the amino acid sequence

MTMKMMVHIYFVSLLLLLFHSYAIDIENEITEFFNKMRTLPK
DSKWLNPACMFGGTMNDIAALGEPFSAKCPPIEDSLLSHRYKDYVVKWERLEKNRRRQ
VSNKRVKHGDLWIANYTSKFSNRRYLCTVTTKNGDCVQGIVRSHIRKPPSCIPKTYEL
GTHDKYGIDLYCGILYAKHYNNITWYKDNKEINIDDIKYSQTGKELIIHNPELEDSGR
YDCYVHYDDVRIKNDIVVSRCKILTVIPSQDHRFKLILDPKINVTIGEPANITCTAVS
TSLIDDLVLEWENPSGWLIGFDFDVSVLTSRGGITEATLYFENVTEEYIGNTYKCR
GHNYFEKTLTTTVVLE (SEQ ID NO:1).

[0036] Calculations of sequence similarity or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows. To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In certain embodiments, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.

[0037] The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

[0038] The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch, (1970, J. Mol. Biol. 48: 444-453) algorithm which has been incorporated into the GAP program in the GCG software package, using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package, using a NWSgapdna. CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used unless otherwise specified) are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

[0039] The percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller (1989, Cabios, 4: 11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

[0040] The term “variant” refers to polynucleotides or polypeptides described herein that are modified at one or more base pairs, codons, introns, exons, or amino acid residues (respectively) yet still retain the ability to bind to, and inhibit, the IFN α family of cytokines. Variants can be produced by any number of means included methods such as, for example, error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, GSSM and any combination thereof..

[0041] The term “saturation mutagenesis” or “GSSM” includes a method that uses degenerate oligonucleotide primers to introduce point mutations into a polynucleotide, as described in detail, below.

[0042] The term “optimized directed evolution system” or “optimized directed evolution” includes a method for reassembling fragments of related nucleic acid sequences, e.g., related genes, and explained in detail, below.

[0043] The term “synthetic ligation reassembly” or “SLR” includes a method of ligating oligonucleotide fragments in a non-stochastic fashion, and explained in detail, below.

[0044] “Combined anti-retroviral therapy” or “cART” refers to combination antiretroviral therapy. “Combined anti-retroviral therapy” or “cART” refers to the combinations of drugs that are used to keep HIV infections under control. These are also commonly referred to as highly active antiretroviral therapy (HAART) regimens and the terminology has further evolved to simply ART for antiretroviral therapy. The combination of anti-retrovirals used in cART can be changed based on drug sensitivities of the subject and drug resistance development.

[0045] Drug combinations used in cART can consist of a minimum of two active drugs from two classes. In some aspects they contain three or more different drugs.

[0046] Medications included in cART include, but are not limited to Nucleotide reverse transcriptase inhibitors (NRTIs), Non-nucleotide reverse transcriptase inhibitors (NNRTIs), Protease inhibitors (PIs), and Integrase inhibitors. Each type of drug can interfere with different stages of the HIV infection and replication process. For example, in some instances, cART comprises Atazanavir, Tenofovir, and Emtricitabine.

[0047] In some aspects, B18R and cART can be formulated together into a single composition. In some aspects, B18R and cART can be formulated independent of each other.

[0048] Disclosed are compositions comprising an IFN α binding protein and/or cART, further comprising a pharmaceutically acceptable carrier. In some aspects, the IFN α binding protein can be B18R or a variant thereof.

[0049] As provided herein, B18R can be a protein produced by a gene from vaccinia virus that can inhibit the action of IFN α by strong binding. In some aspects, B18R can be produced by recombinant DNA procedures in bacterial cells. Any B18R variants that retain the function of binding IFN α can also be used in the disclosed compositions and methods. U.S. Patent Nos. 5,780,027, 7,285,526 and 7,887,814 all provide examples of B18R and methods of making the same, all of which are hereby incorporated by reference in their entirety for their teaching of examples of B18R and methods of making the same.

[0050] As disclosed herein, are pharmaceutical compositions, comprising B18R or a variant thereof and/or cART and a pharmaceutical acceptable carrier described herein. In some aspects, the B18R and/or cART can be formulated for oral or parental administration. In an aspect, the parental administration is intravenous, subcutaneous, intramuscular or direct injection. The compositions can be formulated for administration by any of a variety of routes of administration, and can include one or more physiologically acceptable excipients, which can vary depending on the route of administration. As used herein, the term “excipient” means any compound or substance, including those that can also be referred to as “carriers” or “diluent.” Preparing pharmaceutical and physiologically acceptable compositions is considered routine in

the art, and thus, one of ordinary skill in the art can consult numerous authorities for guidance if needed.

[0051] The compositions can be administered directly to a subject. Generally, the compositions can be suspended in a pharmaceutically acceptable carrier (e.g., physiological saline or a buffered saline solution) to facilitate their delivery. Encapsulation of the compositions in a suitable delivery vehicle (e.g., polymeric microparticles or implantable devices) may increase the efficiency of delivery.

[0052] The compositions can be formulated in various ways for parenteral or nonparenteral administration. Where suitable, oral formulations can take the form of tablets, pills, capsules, or powders, which may be enterically coated or otherwise protected. Sustained release formulations, suspensions, elixirs, aerosols, and the like can also be used.

[0053] Pharmaceutically acceptable carriers and excipients can be incorporated (e.g., water, saline, aqueous dextrose, and glycols, oils (including those of petroleum, animal, vegetable or synthetic origin), starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, ethanol, and the like). The compositions may be subjected to conventional pharmaceutical expedients such as sterilization and may contain conventional pharmaceutical additives such as preservatives, stabilizing agents, wetting or emulsifying agents, salts for adjusting osmotic pressure, buffers, and the like. Suitable pharmaceutical carriers and their formulations are described in "Remington's Pharmaceutical Sciences" by E.W. Martin, which is herein incorporated by reference. Such compositions will, in any event, contain an effective amount of the compositions together with a suitable amount of carrier so as to prepare the proper dosage form for proper administration to the patient.

[0054] The pharmaceutical compositions as disclosed herein can be prepared for oral or parenteral administration. Pharmaceutical compositions prepared for parenteral administration include those prepared for intravenous (or intra-arterial), intramuscular, subcutaneous, intraperitoneal, transmucosal (e.g., intranasal, intravaginal, or rectal), or transdermal (e.g., topical) administration. Aerosol inhalation can also be used. Thus, compositions can be prepared for parenteral administration that includes B18R and/or cART dissolved or suspended in an acceptable carrier, including but not limited to an aqueous carrier, such as water, buffered water, saline, buffered saline (e.g., PBS), and the like. One or more of the excipients included can help approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents, detergents, and the like. Where the compositions

include a solid component (as they may for oral administration), one or more of the excipients can act as a binder or filler (e.g., for the formulation of a tablet, a capsule, and the like).

[0055] The pharmaceutical compositions can be sterile and sterilized by conventional sterilization techniques or sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation, which is encompassed by the present disclosure, can be combined with a sterile aqueous carrier prior to administration. The pH of the pharmaceutical compositions typically will be between 3 and 11 (e.g., between about 5 and 9) or between 6 and 8 (e.g., between about 7 and 8). The resulting compositions in solid form can be packaged in multiple single dose units, each containing a fixed amount of the above-mentioned agent or agents, such as in a sealed package of tablets or capsules.

C. Methods

1. Methods of treating a subject with HAND

[0056] Disclosed are methods of treating a subject with HAND comprising administering a therapeutically effective amount of an IFN α inhibitor comprised of a virus-derived IFN α binding protein. In some aspects, virus-derived IFN α binding protein can be B18R or a variant thereof.

[0057] Disclosed are methods of treating a subject with HAND comprising administering a therapeutically effective amount of B18R or a variant thereof and cART. In some aspects, methods of treating a subject with HAND can comprise administering a therapeutically effective amount of B18R or a variant thereof without cART.

[0058] Disclosed are methods of treating a subject with HAND comprising: identifying a patient in need of treatment; and administering a therapeutically effective amount of B18R or a variant thereof and cART.

[0059] In some instances, identifying a subject in need of treatment comprises determining an increase of IFN α in the cerebrospinal fluid of the subject.

[0060] In some instances, a subject with HAND has previously undergone cART treatment without administering B18R.

[0061] In some instances, the clinical effects of administering a therapeutically effective amount of B18R or a variant thereof and cART can be monitored by determining the levels of IFN α in the serum of the subject being treated.

2. Methods of reversing behavioral abnormalities

[0062] Disclosed are methods of reversing behavioral abnormalities in subjects having HAND comprising administering a therapeutically effective amount of B18R or a variant thereof.

[0063] Disclosed are methods of reversing behavioral abnormalities in subjects having HAND comprising identifying a subject in need of treatment; and administering a therapeutically effective amount of B18R or a variant thereof and cART.

[0064] In some instances, identifying a subject in need of treatment comprises determining an increase of IFN α in the cerebrospinal fluid of the subject. In some instances, identifying a subject in need of treatment comprises clinical history and neuropsychological testing of the subject. In some instances, a identifying a subject in need of treatment comprises a combination of clinical history and neuropsychological testing of the subject and determining an increase of IFN α in the cerebrospinal fluid of the subject.

[0065] In some instances, a subject with HAND has previously undergone cART treatment without administering B18R.

[0066] In some instances, the clinical effects of administering a therapeutically effective amount of B18R or a variant thereof can be monitored by determining the levels of IFN α in the serum of the subject being treated.

3. Methods of reversing the pathology of HIV brain infection

[0067] Disclosed are methods of reversing the pathology of HIV brain infection comprising administering a therapeutically effective amount of B18R or a variant thereof and cART.

[0068] Disclosed are methods of reversing the pathology of HIV brain infection comprising identifying a subject in need of treatment; and administering a therapeutically effective amount of B18R or a variant thereof and cART.

[0069] In some instances, identifying a subject in need of treatment comprises determining an increase of IFN α in the cerebrospinal fluid of the subject.

[0070] In some instances, the subject has previously undergone cART treatment without administering B18R.

[0071] In some instances, the clinical effects of administering a therapeutically effective amount of B18R or a variant thereof and cART can be monitored by determining the levels of IFN α in the serum of the subject being treated.

4. Methods of improving the learning and memory function in a subject infected with HIV

[0072] Disclosed are methods of improving the learning and memory function in a subject infected with HIV comprising administering a therapeutically effective amount of B18R or a variant thereof and cART.

[0073] Disclosed are methods of improving the learning and memory function in a subject infected with HIV comprising identifying a patient in need of treatment; and administering a

therapeutically effective amount of B18R or a variant thereof and cART.

[0074] In some instances, identifying a subject in need of treatment comprises determining an increase of IFN α in the cerebrospinal fluid of the subject. In some instances, identifying a subject in need of treatment comprises clinical history and neuropsychological testing of the subject. In some instances, identifying a subject in need of treatment comprises a combination of clinical history and neuropsychological testing of the subject and determining an increase of IFN α in the cerebrospinal fluid of the subject.

[0075] In some instances, the subject infected with HIV has previously undergone cART treatment without administering B18R.

[0076] In some instances, the clinical effects of administering a therapeutically effective amount of B18R or a variant thereof and cART can be monitored by determining the levels of IFN α in the serum of the subject being treated.

5. Administering

[0077] The disclosed methods comprise a step of administering a therapeutically effective amount of B18R or a variant thereof and cART. In some instances, administering a therapeutically effective amount of B18R or a variant thereof and cART occurs simultaneously. The B18R or a variant thereof and cART can be formulated independently but administered simultaneously. In some instances, B18R or a variant thereof can be formulated with one or more of the antiretroviral compounds present in the cART. Simultaneous administration can be administration of the B18R or a variant thereof and cART at the exact same time, within about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 minutes of each other. In some instances, B18R or a variant thereof and cART are administered within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours of each other. In some instances, B18R or a variant thereof and cART are administered within about 1, 2, 3, 4, 5, 6, or 7 days of each other. In some instances, B18R and cART are administered within about 1, 2, 3, or 4 weeks of each other. In some instances, B18R or a variant thereof and cART are administered within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months of each other.

[0078] In some instances, both the B18R or a variant thereof and cART are administered subcutaneously. Other routes of administration include, but are not limited to, oral, intraperitoneal, buccal, nasal, or intravenous.

[0079] The compositions described herein can be formulated to include a therapeutically effective amount of B18R or a variant thereof and cART described herein. In an aspect, the compositions described herein can be formulated to include a therapeutically effective amount of B18R or a variant thereof and cART described herein. Therapeutic administration encompasses

prophylactic applications. Based on genetic testing and other prognostic methods, a physician in consultation with their patient can choose a prophylactic administration where the patient has a clinically determined predisposition or increased susceptibility (in some cases, a greatly increased susceptibility) to HAND, behavioral abnormalities associated with HAND, or pathology of HIV brain infection.

[0080] The compositions described herein can be administered to the subject (e.g., a human patient) in an amount sufficient to delay, reduce, or preferably prevent the onset of clinical disease. Accordingly, in some aspects, the patient can be a human patient. In therapeutic applications, compositions can be administered to a subject (e.g., a human patient) already with or diagnosed with cancer (or autoimmune disorder) in an amount sufficient to at least partially improve a sign or symptom or to inhibit the progression of (and preferably arrest) the symptoms of the condition, its complications, and consequences. An amount adequate to accomplish this is defined as a "therapeutically effective amount." A therapeutically effective amount of a composition (e.g., a pharmaceutical composition) can be an amount that achieves a cure, but that outcome is only one among several that can be achieved. As noted, a therapeutically effective amount includes amounts that provide a treatment in which the onset or progression of/to HAND, behavioral abnormalities associated with HAND, or pathology of HIV brain infection is delayed, hindered, or prevented. One or more of the symptoms can be less severe. Recovery can be accelerated in an individual who has been treated.

[0081] The therapeutically effective amount or dosage of B18R or a variant thereof and cART or any component of B18R or a variant thereof and cART used in any of the methods as disclosed herein applied to mammals (e.g., humans) can be determined by one of ordinary skill in the art with consideration of individual differences in age, weight, sex, other drugs administered and the judgment of the attending clinician. Variations in the needed dosage may be expected. Variations in dosage levels can be adjusted using standard empirical routes for optimization. The particular dosage of a pharmaceutical composition to be administered to the patient will depend on a variety of considerations (e.g., the severity of the cancer or autoimmune disorder symptoms), the age and physical characteristics of the subject and other considerations known to those of ordinary skill in the art. Dosages can be established using clinical approaches known to one of ordinary skill in the art. In an aspect, the pharmaceutical formulation can be a unit dosage formulation.

[0082] The duration of treatment with any composition provided herein can be any length of time from as short as one day to as long as the life span of the host (e.g., many years). For example, the compositions can be administered once a week (for, for example, 4 weeks to many

months or years); once a month (for, for example, three to twelve months or for many years); or once a year for a period of 5 years, ten years, or longer. It is also noted that the frequency of treatment can be variable. For example, the present compositions can be administered once (or twice, three times, etc.) daily, weekly, monthly, or yearly.

[0083] The total effective amount of the compositions as disclosed herein can be administered to a subject as a single dose, either as a bolus or by infusion over a relatively short period of time, or can be administered using a fractionated treatment protocol in which multiple doses are administered over a more prolonged period of time. Alternatively, continuous intravenous infusions sufficient to maintain therapeutically effective concentrations in the blood are also within the scope of the present disclosure.

D. Kits

[0084] The materials described above as well as other materials can be packaged together in any suitable combination as a kit useful for performing, or aiding in the performance of, the disclosed method. It is useful if the kit components in a given kit are designed and adapted for use together in the disclosed method. For example disclosed are kits comprising B18R or a variant thereof and cART.

Examples

Example 1

[0085] HIV commonly causes HAND despite life-prolonging cART. Substantial evidence shows that IFN α plays a role in HAND pathogenesis. B18R, which binds IFN α , ameliorates HIV induced histopathology, including astrogliosis, microgliosis and reduced neuronal marker, in a HAND mouse model. In this report B18R with cART were co-administered and provide enhanced protection from the above encephalitis markers compared to cART alone in the HAND mouse model. In a separate set of experiments, B18R was tested for its ability to reverse behavioral abnormalities of HAND mice using an Object Recognition Test (ORT). The ORT was administered to HAND mice and controls before and after treatment with B18R. HAND mice treated with B18R showed significant improvement of behavioral impairment compared to untreated HAND mice. Because of its ability to act in concert with cART as well as reverse behavioral abnormalities in HAND mice, B18R is a therapeutic agent for HAND patients.

[0086] A decoy protein that sequesters type I interferons, B18R, ameliorates HIV induced histopathology in a HAND mouse model. An experiment was performed that examined whether B18R plus cART in HAND mice is better than cART alone in ameliorating histopathological markers in the brain. A second study examined whether B18R can reverse behavioral

abnormalities in the HAND model.

A. Experiment 1

1. Materials and Methods

[0087] Primary human monocytes were split into 2 groups: HIV infected and uninfected (control groups). After 1 week in DMEM with M-CSF monocytes/macrophages were infected with 1ml HIV-ADA (MOI of 0.1) for 4 hours. Cells were collected 12 days after HIV infection and resuspended in sterile PBS for intracerebral (IC) inoculation into mice. Ninety percent of macrophages immunostained positive for p24 antigen prior to IC inoculation.

[0088] Four-week old B6.CB17-*Prkdc*^{scid}/SzJ male mice were injected IC in to the right frontal lobe with 10⁵ HIV-infected or uninfected macrophages. There were four groups of mice: control group receiving saline subcutaneously (SC) TID (n=6), HAND mice receiving saline SC TID (n=6), HAND mice receiving combined antiretroviral therapy (cART) SC TID (n=6), and HAND mice treated with cART SC TID and B18R SC BID (n=6).

[0089] HAND mice in the cART group were given SC injections of 300ul 75mg/kg atazanvair TID. They were simultaneously given 120ul of 75mg/kg tenofovir/emtricitabine cocktail SC TID. HAND mice in the cART/B18R group were given cART described earlier plus 200ul of 50ug B18R BID. All mice received repeated SC injections for 10 days.

[0090] Mice were immediately sacrificed after the final injection and brains were extracted and snap frozen. Brains were cryosectioned (5uM) coronally starting at the rostral end of the frontal cortex and ending ¾ through the cerebral hemispheres in the parieto-occipital area. Groups of sections were immunostained for human macrophages (EBM11), HIV (p24 antigen), astrocytes (GFAP), mononuclear phagocytes (CD45) and neurons (MAP2). Staining was assessed through microscopy and densitometry measurements. Viewers were blinded to treatment.

2. Results

[0091] Astrogliosis was significantly decreased in B18R+cART treated HAND mice compared to untreated HAND mice (Figure 1A). HAND mice treated with B18R and cART had significantly less immunostaining for mononuclear phagocytes (i.e. macrophages and microglia) than untreated HAND mice (Figure 1B). Both astrogliosis and microgliosis were reduced to levels seen in control mice in HAND mice with B18R + cART treatment (Figures 1A and 1B). More importantly, B18R + cART treated HIV mice were significantly protected against a reduction in dendritic arborization (Figure 1C).

B. Experiment 2

1. Materials and Methods

[0092] Four-week old B6.CB17-Prkdcscid/SzJ male mice were injected IC (Day 0 or D0) in to the right frontal lobe with 105 HIV-infected or uninfected macrophages (Figure 2). There were three groups of mice, control group (n=9), HAND mice without treatment (n=9), and HAND mice with B18R treatment (n=9). On D4 the mice experienced 10 minutes of acclimatization to a Plexiglas chamber (60 cm x 60 cm). On D5 the procedure consisted of a training phase, followed by a preference test after a delay of 5 min (Figure 3). In the training phase, duplicate copies of an object were placed near the two corners at opposite sides of the arena (15 cm from each adjacent wall). The animal was placed into the arena and allowed a total of 5 minutes of exploration of the two identical objects (Figure 2A). During preference test or novel object testing (5 min duration), the animal was replaced in the arena, presented with two objects in the same positions: one object was one of the identical objects used in the training phase (A), and the other object was a novel object (B). Exploration times were recorded and used to calculate a discrimination index [time spent with object A minus time spent with object B] / [total time exploring both objects] for the training session and for the test session.

Discrimination indices of 0 indicate equal exploration of both objects.

[0093] On the next day (D6) all mice were shown two different identical objects (different from identical object pair in training phase on D5)(Figure 2B) in the training phase and after a 2 hr. delay the original object and a novel object for the testing phase. From D6-D13 mice HAND mice and control groups were given 200ul saline SC BID. B18R treatment was given 200ul of B18R (50ug/inj) SC BID to another group of HAND mice. On D12 all mice were given a training phase followed by a 5 minute delayed preference test (Figure 2C). On the next day (D13) mice were given a training phase and then after a 2 hour delay given a preference test. All objects used on all days were used only for that day (Figure 3D). Treatment continued during training and testing D12 and D13. Mice were sacrificed on D14 after testing was completed and brains were snap frozen.

2. Results

[0094] On D5 all mice can discriminate novel vs familiar object (Figure 4A). However, controls discriminate better than HAND mice. On D6 control mice discriminate substantially better than HAND mice on a more difficult ORT (2 hr delay) test (Figure 4B). On D12, control and B18 treated HAND mice discriminate but untreated (receiving saline) HAND mice were not able to discriminate the 5 min ORT delay test (Figure 4C). This is in contradistinction to D5

when untreated HAND mice were able to discriminate objects. On D13 after a 2 hr delay B18R treated HAND mice discriminate objects significantly better than untreated (saline) HAND mice (Figure 4D).

3. Conclusions

[0095] B18R plus cART is superior to cART alone in ameliorating brain histopathology in this HAND mouse model. These abnormalities include potentially important markers in HAND such as astrogliosis, microgliosis and dendritic simplification. Astroglia and microglia represent cells types that are activated during HIV infection of the CNS and produce neurotoxins, including IFN α , that adversely affect neurons. Furthermore, the findings are important because if B18R is shown to be safe and effective in humans with HAND, it would be used as an add-on treatment.

[0096] The second experiment shows that B18R significantly reverses behavioral abnormalities in HAND mice. Novel agents tested in animal models of HAND ideally should show reversibility of behavioral abnormalities. There are several reasons that support this assertion. ANI and MND are the most common forms of HAND and by definition represent cognitive disorders that are relatively subtle compared to dementia. Like mild cognitive impairment in Alzheimer's disease, ANI and MND likely can lead to HAD and early treatment could prevent or slow progression. Because HAND mice do not have overt behavioral disturbances and need behavioral testing to demonstrate abnormalities, they are comparable to humans with ANI and MND. Early cognitive disturbances in HAND can be reversible with cART, representing neuronal dysfunctional, not death. The data presented in our second study are analogous to reversing cognitive dysfunction in humans with HAND.

[0097] Like previous clinical and translational studies that support the role of IFN α in HAND, the data presented here provide additional evidence that IFN α is produced and is neurotoxic during HIV infection of the brain. We believe our studies provide substantial impetus to precede to a Phase I trial of B18R in patients with HAND.

Example 2

Reversing interferon-alpha neurotoxicity in a HIV-associated neurocognitive disorders mouse model

1. Introduction

[0098] HIV-associated neurocognitive disorders (HAND) remain a concern even in the combined antiretroviral therapy (cART) era. HAND affects approximately half of people living with HIV. In cART patients milder forms of HAND (e.g. mild neurocognitive disorder) are

predominant. These milder forms of HAND eventually lead to HIV associated dementia, which results in substantial morbidity and mortality. Another concern is with prolonged life due to cART, aging HIV-infected individuals are more susceptible to cognitive decline. Associated comorbidities likely accelerate this process. Therefore, there is a need to develop adjunctive [to cART] therapies for HAND.

[0099] A model of HIV encephalitis (HIVE) was developed and refined to include behavioral parameters, which reflect cognitive deficits in humans with HAND. This model enabled testing of cART and its effects on histopathology and mouse behavior. Other studies in HAND mice correlated behavioral and histopathological findings with the presence of IFN α in mouse brain. These mouse studies were undertaken because clinical research has indicated that IFN α is present in the brains of patients with HIVE (i.e., pathological studies) and HAND, and that IFN α cerebrospinal fluid levels correlate with cognitive dysfunction. IFN α also correlates with behavioral abnormalities in HAND mice; these behavioral abnormalities and the corresponding histopathological features were prevented when neutralizing antibodies to IFN α or when a novel IFN α binding protein, B18R, were administered systemically.

[00100] In vitro studies have shed light on the mechanisms of IFN α neurotoxicity. Exposure of rat neuronal cultures to IFN α results in dendritic simplification, which is mediated through both the Type I IFN receptor (IFNAR) and the NMDA receptor (NMDAR). Furthermore, the GluN2A subunit of the NMDAR is specifically involved in IFN α neurotoxicity. Determining the mechanisms of IFN α neurotoxicity is important. Indeed, these mechanisms could be generalizable to other neurodegenerative diseases, and blocking IFN α directly may not be practical in humans, depending on the exact disease and individual patient responses.

[00101] Taking these considerations into account, it was determined if IFN α neurotoxicity is reversible in HAND mice. Here refinements of the HAND model are presented using object recognition tasks (ORT). ORT has enabled testing of B18R after behavioral abnormalities develop in HAND mice to determine reversibility of ORT abnormalities. This is a critical component of animal model testing since it reflects what would occur when treating patients who are discovered to have HAND. In addition, an in vitro rat neuronal system was used to further investigate the effects of IFN α on dendritic structure, specifically the presence of Post Synaptic Density (PSD)-95 in dendritic spines and the possible signaling mechanisms involved in IFN α neurotoxicity.

2. Methods

i. In vitro:

a. Rat neuronal cultures:

[00102] Rat neurons were either obtained from Brain Bits (Cat # SDECX; embryonic day 18) and cultured in NBACTIV1 media (Cat # nbactiv1) until day 14, when they are relatively “mature”, or cortical neurons were prepared from embryonic day 18 Sprague Dawley fetuses. Two different densities of neurons were utilized, based on test procedures. For PSD-95 puncta, low density cultures (10,000 neurons/cm²) were placed on 12mm poly D Lysine (Sigma cat #2636) coated coverslips, incubated in wells with glia (astrocytes) or removed for IFN α (300 IU/ml) exposure. High density cultures (500,000 neurons/60 mm dish) were used for protein extraction. These cultures contained approximately 2-3% glia (GFAP immunostaining).

b. SDS-PAGE/ Western Blotting:

[00103] Protein samples (5 to 10 micrograms) were resolved in Criterion precast gels (Bio-Rad) and transferred to a PVDF membrane using a semidry system (Bio-Rad). All blocking antibody and washing steps were performed at room temperature (RT) on a rocker. Membranes were incubated for one hour in 3% non-fat dry milk in TBST (25 mM Tris, 140mM NaCl, 3mM KCl, and 0.05% Tween-20), then 4 hr in anti-Arfl antibody (cat # ARP75924_P050, Aviva; 1:1000) diluted in 1% non-fat dry milk in TBST. Membranes were briefly washed in TBST followed by 3 separate 5 minute incubations in TBST. Membranes were incubated for one hour with goat anti-rabbit IgG HRP (cat # NEF812001EA, Perkin Elmer 1:5,000) diluted in 1% non-fat dry milk in TBST. Final washing included a quick rinse with ddH₂O, 2 min wash in TBST, 4 min wash in TBST, and 5 min wash in 1X TBS. Immunoreactive bands were detected with chemiluminescence using ECL Prime substrate (cat # RPN2236, GE Healthcare Life Sciences) on a Chemidoc imager (Bio-Rad), and quantified with ImageJ (NIH). Arfl signal was normalized to GAPDH Western blot (WB) intensity (cat # MAB374, Millipore; 1:20,000).

c. PSD-95:

[00104] Rat neurons were seeded on poly-L-lysine coated coverslips and co-cultured with astroglia. On day 14, half of the conditioned medium from co-culture was transferred to new 6 well plates. To the conditioned medium, IFN α (300 IU/mL) or sterile water (used to reconstitute IFN α) was added, and coverslips with neurons were transferred from co-culture plates and placed in IFN α - (or vehicle-) containing plates. After 20 min or 2 hrs, neurons on coverslips were rinsed once in 1X PBS at RT and fixed in fresh 4% paraformaldehyde in 1X PBS for 5 minutes and rinsed in 1X TBS. Neurons were permeabilized in 0.3% Triton X in 1X TBS, blocked with 2% goat and 2% horse serum in 1X TBS, and incubated with antibodies against

MAP2 (cat #5622 Millipore and 1:100) and PSD-95 (cat # NB300-556 Novus Biologicals and 1:1000) in buffer (2% BSA in 1X TBS). Secondary antibodies were fluorescein-conjugated for MAP2 (cat # FI-1000, Vector Laboratories) and Texas Red-conjugated for PSD-95 (cat # TI-2000, Vector Laboratories) and applied for 30 minutes at 1:1000 in antibody buffer. After mounting in antifade reagent, images of 5 neurons/coverslip (i.e., 10 neurons/treatment group) were taken on an Olympus BX51 with Olympus DP80 camera. PSD-95 puncta were identified and counted with SYNAPANAL software. For each neuronal image, dendrites were traced a distance of 40 linear units (SYNAPANAL defined unit) starting at the first branch point of the dendrite from the soma. PSD-95 puncta along the region were counted and divided by the length to obtain PSD-95 puncta/unit. For each neuron PSD-95 puncta/unit was computed from the dendrites traced for that neuron (2 to 4). For each treatment, the average puncta/unit was determined by averaging the puncta/unit for each neuron (at least 10/treatment in each replicate plate). For each treatment within the experiment, the average puncta/unit is determined by averaging the puncta/unit for each replicate of that treatment (thus, n=3/treatment) for 20 min and 2 hours.

d. AMPA Receptor Immunofluorescent Staining:

[00105] Rat neurons were fixed with 4% paraformaldehyde in PBS for 20 min at RT. They were incubated with anti-GLuR2 (EMD Millipore, Burlington Massachusetts; 1:100), a subunit of the AMPA receptor (AMPA), for 1 hour at RT in the dark. After washes, this was followed by incubation with DAPI 500 mM 17 (Images were subjected ImageJ software for densitometric analysis).

e. Proteomics:

[00106] For proteomic analysis of total protein, rat cortical neurons were cultured in 60 mm dishes in high density (described above). After 14 days, cells were treated with 300 IU/mL IFN α for 20 min, 2 hr, 8 hr, 24 hr, or 48 hr. For comparison of the proteome, untreated cells were given sterile, distilled water (vehicle) equal to the volume of IFN α . After incubations, cells were washed once in RT phosphate buffered saline (PBS) and scraped into 500 microliters of PBS. Cell slurries were snap frozen in a dry ice ethanol bath and processed by the Emory University Proteomics Core.

[00107] To select proteins for further analysis, GO-Elite software was used. GOElite identified gene ontology (GO) terms as significantly down-regulated by analyzing lists of protein accession numbers from each data set (20 min, 2 hr, 8 hr, 24 hr, 48 hr) and comparing to a list of accession numbers from the vehicle-treated sample. These lists of accession numbers were derived by identifying proteins for which the total peptide spectral match (PSM) was

seven-fold (or more) lower in the IFN α treated sample than in the control sample. The Arf1 protein belonged to groups of GO terms (primarily G-protein signaling) that were down-regulated for all IFN α treated cultures and for which a relationship to neuron projections had been established. Thus, Arf1 was selected for WB analysis.

ii. In vivo:

a. Animals:

[00108] Five week old B6.CB17-Prkdc/Szj (SCID) male mice were purchased from Jackson Laboratory (Bar Harbor, ME), singly housed in sterile micro-isolator cages and given 1 week to acclimate before experimentation. All protocols were approved by the Atlanta VA Institutional Animal Care and Use Committee. SCID mice carry the severe combined immune deficiency mutation (caused by a spontaneous mutation in the Prkdc gene) on the C57BL/6J strain background. These mutant mice do not have functional T or B cells (lack the T cell receptor and competent antibody), thus supporting allogeneic and xenogeneic grafts.

b. Infection:

[00109] Purified, primary human monocytes (1×10^8) were purchased from Dr. Howard Gendelman, University of Nebraska, and grown in Dulbecco's modified eagle medium. After 7 days, half (approximately 5×10^7) of the cells were infected with HIV-1ADA. The uninfected and infected human monocytes were cultured for 2 weeks. To determine the in vitro infection rate, infected cells on slides were stained for p24 antigen (see "Tissue Sectioning and Immunostaining" for methods). About 90% of the cells expressed p24. Infected and uninfected human monocyte derived macrophages (MDM) were resuspended in sterile PBS at 100,000 cells per 30 μ l for inoculation. Infected (HIV or HAND mice) and uninfected MDM (Control mice) were injected intracerebrally (IC) into the right frontal lobe.

c. Antiretroviral Drug Preparation and B18R Drug Preparation:

[00110] Atazanavir (Bristol-Meyers Squibb) was dissolved in sterile water at a concentration of 5mg/ml. Tenofovir (Gilead Sciences, Inc.) was dissolved in sterile water at 13mg/ml. Emtricitabine (Gilead Sciences, Inc.) was dissolved in sterile water at 100mg/ml. As atazanavir would not dissolve with tenofovir and emtricitabine, it was injected into mice subcutaneously (SC) separately. Dosages for the antiretroviral drugs (ARV) were based on a previous study showing them to be effective and measurable in the brain after systemic administration. B18R (NormferonTM, a gift from Meigen Biotechnology Corp.) was produced using modified standard recombinant procedures and purified to a single band on a PAGE gel using cation exchange. For in vivo potency estimation, a test of B18R was run in non-immunocompromised animals. Each mouse of the HIV-B18R group received 50 μ g of B18R per day suspended in

300 μ L of PBS in divided doses (150 μ L $\times$ 2 times a day), which was given either from the time of human MDM IC inoculation (cART plus B18R histopathological study – see below) or 6 days later (Behavioral study – see below) until the mice were sacrificed. B18R concentration was measured using the microBCA assay (Thermofisher). Serum half-life was estimated using IFN ELISA measurements (PBL kit) in polyI:C (EMD Millipore) induced C57/BL6 mice. The time point after B18R injection at which the B18R could no longer reduce serum IFN by 50% was used as a preliminary guide to serum half-life (4.5 hours). B18R crosses the blood brain barrier and is detectable in brain parenchyma.

d. Antiretroviral & B18R Therapy:

[00111] For the histopathological study, there were four groups of mice: control group (n=9), HIV infected without treatment (n=9), HIV infected with antiretroviral (ARV = cART) treatment (n=7) and HIV infected with both ARV and B18R treatment (n=7). All mice received SC injections for 10 days of either 0.9% NaCl (n=12) or ARV at a dose of 75 mg/kg/injection (inj) (n=12). This dose was based on a previously published experiment 20. ARV injections started immediately following IC inoculation of HIV-infected or uninfected human MDM. ARV was administered at 7:30AM, 11:30AM and 3:30PM. Immediately after IC inoculation with either infected or uninfected MDM, HIV infected mice in the ARV and B18R group also received B18R treatment. Each mouse received 2 SC injections of B18R per day over a period of 10 days at 9:30 am and 1:30 AM. Mice were sacrificed on D10 following the final injections. Brains were snap frozen for tissue sectioning.

e. Behavioral and B18R Treatment Study:

[00112] Four-week old B6.129S7-Rag 1 tm1Mom/J male mice were injected IC (Day 0 or D0) with 10^5 HIV-infected or uninfected human MDM (Supplemental Figure 1). There were three groups of mice: control group (n=9), HIV infected without treatment (n=9), and HIV infected with B18R treatment (n=9). From D6 through D13, mice in HIV and control groups were given 200ul saline SC BID. Mice in the B18R treatment group were given 200ul of B18R (50ug/inj) SC BID.

f. Object Recognition Behavioral Testing:

[00113] On D4 the mice experienced 10 minutes of acclimation to the Plexiglas chamber (60 cm x 60 cm) used for all object recognition training and testing. On D5 the procedure consisted of a training phase, followed by a 5 minute delay, and then a preference test (Figure 8). In the training phase, duplicate copies of an object were placed near the two corners at either end of opposite sides of the arena (15 cm from each adjacent wall). The animal was placed into the arena and allowed 5 minutes of exploration of objects. During preference/novel object testing (5

minute duration), the animal was replaced in the arena, presented with two objects in the same positions: one object was one of the identical objects used in the training phase (A), and the other object was a novel object (B). For data scoring, the analyst was blinded to treatment. Exploration times were recorded and used to calculate a discrimination index [time spent with object A - time spent with object B] / [total time exploring both objects] for training and test sessions. Discrimination indices of 0 indicated equal exploration of both objects. On the next day (D6) all mice were shown two different identical objects in the training phase, and after a 2 hour delay, an old and novel object in the testing phase. From D6 through D13, mice received treatments. On D12, all mice were given a training phase, a 5 minute delay, and then a preference test. On the next day (D13) mice were given a training phase, a 2 hour delay, and then a preference test. For any given day, all utilized objects were used only for that day. Treatment continued during training and testing for D12 and D13. Mice were sacrificed on D13 after testing was completed.

g. Tissue Sectioning and Immunostaining:

[00114] Mouse brains (B18R plus ARV study only) were sectioned and stained. Briefly, starting rostrally (frontal lobe), fifty 5µm coronal sections were stained using an immunoperoxidase method for HIV (p24, 1:20, Dako), human macrophages (EBM11, 1:50, Dako), astrogliosis (anti-glial fibrillary acidic protein or GFAP, 1:750, Millipore), mouse mononuclear phagocytes (CD45, 1:50, AbDSerotec), and neurons and processes (anti-microtubule-associated protein 2 or MAP 2, 1:200, Millipore). The sections were examined under light microscopy (Olympus BX51).

h. Densitometry:

[00115] The evaluator was initially blinded to treatment status. Microscopic images of the tissue sections were taken at varying magnifications: GFAP at 4X and MAP 2 and CD45 at 20X. Each image consisting of 900 X 672 pixels was captured using Image-Pro Express software on a Windows computer. Tiff images were imported into NIH ImageJ. They were then set to 8 bit mono, the correct measurement parameters set, and the desired area of tissue was selected and measured. The intensities of the treatment group sections were compared to the control and HIV+ untreated sections. MAP2 expression was examined differently. MAP2 sections with reduced staining in the area of the xenograft within the right hemisphere were compared via densitometry with similar anatomical areas of the uninoculated left hemisphere to determine the percent decrease in MAP-2 expression.

i. Statistical Analyses:

[00116] SPSS software was used for statistical analyses. An analysis of variance (ANOVA)

with Tukey's post hoc test was used to compare differences in pathology. A t-test was used to compare differences in viral load of p24 counts. A two-way repeated measures ANOVA model was used to analyze PSD95 puncta density using GraphPad Prism 7. Factors were treatment (interferon and vehicle) and time (20 min and 2 hr). Data were paired within each of the 3 separate neuron preparation batches. A post-hoc test p value of <0.05 was considered significant for in vitro and in vivo experiments. An analysis of variance (ANOVA) with Tukey's post hoc test was used to compare differences in behavior. A p value of <0.05 was considered significant.

3. Results

i. B18R reverses behavioral abnormalities in HAND mice:

[00117] On Day 5, all mice could discriminate the novel vs. familiar object. However, Control mice (injected IC with uninfected human MDM) discriminated better than HAND mice (injected IC with HIV-infected human MDM; data not shown). On Day 6, only Control mice discriminated on the more difficult ORT 2 hour delay test (Fig 4B); HIV (i.e., HAND) mice could not discriminate the novel object with this increased temporal demand. On D12, Control and B18R treated mice discriminated, but untreated (saline) HIV mice did not discriminate the ORT test with the 5 min delay, which they were once able to discriminate on Day 5 (data not shown). On D13, HIV mice that were once unable to discriminate on D6 (Fig 4B), now having been treated with B18R for 6 days, discriminated on D13 during a more difficult ORT task (Fig 4D). Untreated HIV mice were unable to discriminate on 2hr delay ORT on Day 6 and Day 13.

ii. B18R plus cART improves HAND histopathology:

[00118] B18R plus ARV significantly prevents astrogliosis compared to HAND (labeled "HIV" in Figure 1) mice (injected with HIV-infected human MDM) given saline (Fig 1A). Immunostaining for the presence of mouse mononuclear phagocytes is also significantly attenuated by B18R plus ARV treatment compared to HAND mice given saline (Fig 1B). Finally, a marker of neuronal dendrites (MAP2) is relatively preserved in HAND mice given B18R plus ARV compared to saline (Fig 1C). In contrast, HAND mice treated with ARV (Fig 1 A, B and C, HIV+ARV columns) were not statistically different from HAND mice given saline (HIV-saline), although results suggest improvement of histopathology in HAND mice given ARV relative to saline only.

iii. IFN α decreases PSD-95 puncta on rat neurons:

[00119] Twenty minutes and 2 hours after IFN α exposure PSD-95 puncta are significantly decreased on rat neurons compared to control neurons (Fig 5 and Figure 9).

iv. IFN α decreases Arf1 in rat neurons:

[00120] Proteomic analyses revealed decreased Arf1 levels in rat neuronal cultures exposed to IFN α . Figure 6 depicts WB verification of proteomics data and is representative of 4 experiments. There are decreases in Arf1 at 2 and 4 hours after IFN α exposure. Arf1 was also decreased at 8 hours, but not consistently at 24 hours (data not shown).

v. IFN α decreases AMPA Receptor expression on rat neurons:

[00121] Rat neuronal surface expression of AMPARs is significantly decreased in rat neurons exposed to IFN α for 2 hours (Fig 7). Data are representative of 2 separate experiments

4. Discussion

[00122] B18R is a biologic cloned from the Vaccinia virus and is able to bind Type I IFNs with high affinity (K_d 174 pM) 21. When B18R was administered to HAND mice after they developed behavioral deficits on the ORT (Figure 4), it reversed these behavioral abnormalities after 6 to 7 days of treatment. When B18R was combined with a cART regimen, important histopathological features of HAND mice, such as increases in microgliosis and astrogliosis, and decreases in the neuronal marker MAP2, were ameliorated (Figure 1). These data also indicate that B18R, when combined with cART, improves pathological markers of HAND to a greater extent than cART alone.

[00123] These findings are consistent with previous studies showing that systemic treatment with either neutralizing antibodies to IFN α or B18R essentially prevents behavioral and histopathological abnormalities in HAND mice respectively. More importantly, they extend previous findings by showing that B18R can reverse behavioral deficits, and when combined with cART, likely improves HAND pathology more than cART alone. It was not tested whether cART alone could improve behavior because it was previously demonstrated that it had no effect in the HAND model. The significance of this preclinical testing of B18R is that in a practical clinical setting, HIV infected patients are often already taking cART and must first be identified with HAND before a specific cognitively targeted treatment can be initiated. The data indicate that in cART HIV patients, B18R treatment could be introduced after cognitive dysfunction is detected. Moreover, the current data, combined with the landscape from prior research, indicate that this combination treatment would result in improvement of symptoms such as concentration and memory impairment and demonstrate a strong impetus for Phase I testing in HAND patients.

[00124] Although there is evidence that people living with HIV with increased systemic IFN α levels may have worse clinical outcomes, there is concern that inhibiting Type I IFNs (e.g., B18R treatment) could result in increased viral loads, even in patients already receiving cART.

There could be other untoward effects of inhibiting Type I IFNs, such as increased susceptibility to other infections. With this in mind, the mechanisms of IFN α neurotoxicity was investigated with the idea that this can lead to the development of novel therapeutics that are more specific in preventing neuronal dendritic simplification and better tolerated. In addition, these treatments might be more applicable to a broad spectrum of neurodegenerative diseases.

[00125] It is believed that alterations in neuronal dendrites and synapses in vitro are reflections of neuronal connectivity in vivo, and that the ability of neurons to make connections through healthy dendrites and synapses is representative of cognitive functions. Previous in vitro studies demonstrated that exposure of rat neurons to IFN α results in shortened dendritic processes with less branching. The current findings of decreased PSD-95 on dendritic spines (Figure 5) expands previous findings to a fundamental element of neuronal transmission and memory: the synapse. PSD-95 is present on dendritic spines and increases in spine density likely reflect memory consolidation. Conversely, decreased dendritic spine density has been found at autopsy in patients with HIV encephalitis.

[00126] Arf1 is also decreased in neurons exposed to IFN α (Figure 6). Arf1 is a small GTP binding protein and blocks PICK1, which inhibits Arp2/3. Arp2/3 promotes F-actin stabilization of PSD-95 complexes and AMPA receptors. In addition, it was found that after 2 hours of IFN α exposure rat neurons exhibited reduced expression of AMPARs (Fig 7). By decreasing Arf1, IFN α can destabilize F-actin resulting in decreases in PSD-95 expression, leading to AMPA receptor internalization. This results in decreased plasticity and long-term depression in affected neurons, and thus, cognitive dysfunction. However, the time sequence of decreased Arf1 (starting 2 hrs after IFN α exposure) and decreased PSD-95 puncta (starting at 20 min after IFN α exposure) shown in this study indicates that either Arf1 decreases are unrelated to reduced PSD-95 expression, or that there are two mechanisms leading to decreased PSD-95 expression and decreased surface AMPAR expression that are occurring in parallel. In either case, the in vitro findings indicate that signaling pathways leading to decreases in PSD-95 expression and loss of surface AMPAR expression are fundamental to cognitive dysfunction caused by IFN α .

[00127] In summary, the present findings and clinical data showing correlation of CSF IFN α levels with cognitive dysfunction in HAND patients lend substantial support for a Phase I trial of B18R in this patient population. In addition, there is growing evidence that IFN α plays a broader role in other neuroinflammatory and neurodegenerative disorders, such as Alzheimer's disease.

[00128] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the method and

compositions described herein. Such equivalents are intended to be encompassed by the following claims.

REFERENCES

1. Heaton RK, Clifford DB, Franklin DR, Jr., et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. *Neurology*. 2010 Dec 7;75(23):2087-96.
2. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. *Neurology*. 2007 Oct 30;69(18):1789-99.
3. Saylor D, Dickens AM, Sacktor N, et al. HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment. *Nat Rev Neurol*. 2016 Apr;12(4):234-48.
4. Grant I, Franklin DR, Jr., Deutsch R, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. *Neurology*. 2014 Jun 10;82(23):2055-62.
5. Rumbaugh JA, Tyor W. HIV-associated neurocognitive disorders: Five new things. *Neurol Clin Pract*. 2015 Jun;5(3):224-31.
6. Tyor WR, Power C, Gendelman HE, Markham RB. A model of human immunodeficiency virus encephalitis in scid mice. *Proc Natl Acad Sci U S A*. 1993 Sep 15;90(18):8658-62.
7. Avgeropoulos N, Kelley B, Middaugh L, et al. SCID mice with HIV encephalitis develop behavioral abnormalities. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1998 May 1;18(1):13-20.
8. Cook JE, Dasgupta S, Middaugh LD, et al. Highly active antiretroviral therapy and human immunodeficiency virus encephalitis. *Ann Neurol*. 2005 Jun;57(6):795-803.
9. Cook-Easterwood J, Middaugh LD, Griffin WC, 3rd, Khan I, Tyor WR. Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis. *Exp Neurol*. 2007 Jun;205(2):506-12.
10. Sas AR, Bimonte-Nelson HA, Tyor WR. Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of Interferon-alpha in the brain. *AIDS*. 2007 Oct 18;21(16):2151-9.
11. Fritz-French C, Tyor W. Interferon-alpha (IFNalpha) neurotoxicity. *Cytokine Growth Factor Rev*. 2012 Feb-Apr;23(1-2):7-14.

12. Anderson AM, Lennox JL, Mulligan MM, et al. Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals. *J Neurovirol.* 2017 Feb;23(1):106-12.
13. Sas AR, Bimonte-Nelson H, Smothers CT, Woodward J, Tyor WR. Interferon-alpha causes neuronal dysfunction in encephalitis. *J Neurosci.* 2009 Mar 25;29(12):3948-55.
14. Fritz-French C, Shawahna R, Ward JE, Maroun LE, Tyor WR. The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse model. *J Interferon Cytokine Res.* 2014 Jul;34(7):510-7.
15. Kessing CF, Tyor WR. Interferon-alpha induces neurotoxicity through activation of the type I receptor and the GluN2A subunit of the NMDA receptor. *J Interferon Cytokine Res.* 2015 Apr;35(4):317-24.
16. Tyor WR, Bimonte-Nelson H. A mouse model of HIV-associated neurocognitive disorders: a brain-behavior approach to discover disease mechanisms and novel treatments. *J Neurovirol.* 2017 Sep 11.
17. Rui Y, Myers KR, Yu K, et al. Activity-dependent regulation of dendritic growth and maintenance by glycogen synthase kinase 3beta. *Nat Commun.* 2013;4:2628.
18. Zambon AC, Gaj S, Ho I, et al. GO-Elite: a flexible solution for pathway and ontology over-representation. *Bioinformatics.* 2012 Aug 15;28(16):2209-10.
19. Rocca DL, Amici M, Antoniou A, et al. The small GTPase Arp1 modulates Arp2/3-mediated actin polymerization via PICK1 to regulate synaptic plasticity. *Neuron.* 2013 Jul 24;79(2):293-307.
20. Koneru R, Olive MF, Tyor WR. Combined antiretroviral therapy reduces brain viral load and pathological features of HIV encephalitis in a mouse model. *J Neurovirol.* 2014 Feb;20(1):9-17.
21. Symons JA, Alcamí A, Smith GL. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. *Cell.* 1995 May 19;81(4):551-60.
22. Gringeri A, Musicco M, Hermans P, et al. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study). *J Acquir Immune Defic Syndr Hum Retrovirol.* 1999 Apr 1;20(4):358-70.
23. Utay NS, Douek DC. Interferons and HIV Infection: The Good, the Bad, and the Ugly. *Pathog Immun.* 2016 Spring;1(1):107-16.

24. Benitez-King G, Ramirez-Rodriguez G, Ortiz L, Meza I. The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia. *Curr Drug Targets CNS Neurol Disord.* 2004 Dec;3(6):515-33.
25. Lin YC, Koleske AJ. Mechanisms of synapse and dendrite maintenance and their disruption in psychiatric and neurodegenerative disorders. *Annu Rev Neurosci.* 2010;33:349-78.
26. Tada T, Sheng M. Molecular mechanisms of dendritic spine morphogenesis. *Curr Opin Neurobiol.* 2006 Feb;16(1):95-101.
27. Masliah E, Ge N, Morey M, DeTeresa R, Terry RD, Wiley CA. Cortical dendritic pathology in human immunodeficiency virus encephalitis. *Lab Invest.* 1992 Mar;66(3):285-91.
28. Masliah E, Heaton RK, Marcotte TD, et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. *Ann Neurol.* 1997 Dec;42(6):963-72.
29. Taylor JM, Minter MR, Newman AG, Zhang M, Adlard PA, Crack PJ. Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer's disease. *Neurobiol Aging.* 2014 May;35(5):1012-23.

CLAIMS

We claim:

1. A composition comprising an interferon-alpha (IFN α) binding protein and combined anti-retroviral therapy (cART).
2. The composition of claim 1, wherein the IFN α binding protein is B18R or a variant thereof.
3. The composition of claims 1-2, further comprising a pharmaceutically acceptable carrier.
4. A pharmaceutical composition comprising the composition of any one of claims 1-3 and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is formulated for intravenous administration.
6. A method of treating a subject with HIV associated neurogenerative disorder (HAND) comprising administering a therapeutically effective amount of B18R or a variant thereof and cART.
7. The method of claim 6, wherein administering a therapeutically effective amount of B18R or a variant thereof and cART occurs simultaneously.
8. The method of any one of claims 6-7, wherein the subject with HAND has previously undergone cART treatment without administering B18R.
9. The method of any one of claims 6-8, wherein the cART comprises Atazanavir, Tenofovir, and Emtricitabine.
10. The method of any one of claims 6-9, wherein both the B18R or a variant thereof and cART are administered subcutaneously.
11. A method of reversing behavioral abnormalities in subjects having HAND comprising administering a therapeutically effective amount of B18R or a variant thereof.
12. The method of claim 11, wherein the subject with HAND has previously undergone cART treatment.

13. The method of any one of claims 11-12, wherein the B18R or a variant thereof is administered subcutaneously.
14. A method of reversing the pathology of HIV brain infection comprising administering a therapeutically effective amount of B18R or a variant thereof and cART.
15. The method of claim 14, wherein administering a therapeutically effective amount of B18R or a variant thereof and cART occurs simultaneously.
16. The method of any one of claims 14-15, wherein the cART comprises Atazanavir, Tenofovir, and Emtricitabine.
17. The method of any one of claims 14-16, wherein both the B18R or a variant thereof and cART are administered subcutaneously.
18. A method of improving the learning and memory function in a subject infected with HIV comprising administering a therapeutically effective amount of B18R or a variant thereof and cART.
19. The method of claim 18, wherein administering a therapeutically effective amount of B18R or a variant thereof and cART occurs simultaneously.
20. The method of any one of claims 18-19, wherein the subject infected with HIV has previously undergone cART treatment without administering B18R.
21. The method of any one of claims 18-20, wherein the cART comprises Atazanavir, Tenofovir, and Emtricitabine.
22. The method of any one of claims 18-21, wherein both the B18R or a variant thereof and cART are administered subcutaneously.
23. A method of treating a subject with HAND comprising:
 - a. identifying a subject in need of treatment; and
 - b. administering a therapeutically effective amount of B18R or a variant thereof and cART.

24. The method of claim 23, wherein identifying a subject in need of treatment comprises determining an increase of IFN α in the cerebrospinal fluid of the patient.
25. The method of any one of claims 23-24, wherein administering a therapeutically effective amount of B18R or a variant thereof and cART occurs simultaneously.
26. The method of any one of claims 23-25, wherein the subject with HAND has previously undergone cART treatment without administering B18R.
27. The method of any one of claims 23-26, wherein the cART comprises Atazanavir, Tenofovir, and Emtricitabine.
28. The method of any one of claims 23-27, wherein both the B18R or a variant thereof and cART are administered subcutaneously.
29. A method of reversing behavioral abnormalities in subjects having HAND comprising
 - a. identifying a subject in need of treatment; and
 - b. administering a therapeutically effective amount of B18R or a variant thereof and cART.
30. The method of claim 29, wherein identifying a subject in need of treatment comprises determining an increase of IFN α in the cerebrospinal fluid of the patient.
31. The method of any one of claims 29-30, wherein administering a therapeutically effective amount of B18R or a variant thereof and cART occurs simultaneously.
32. The method of any one of claims 29-31, wherein the subject with HAND has previously undergone cART treatment without administering B18R.
33. The method of any one of claims 29-32, wherein the cART comprises Atazanavir, Tenofovir, and Emtricitabine.
34. The method of any one of claims 29-33, wherein both the B18R or a variant thereof and cART are administered subcutaneously.
35. A method of reversing the pathology of HIV brain infection comprising
 - a. identifying a subject in need of treatment; and

- b. administering a therapeutically effective amount of B18R or a variant thereof and cART.
- 36. The method of claim 35, wherein identifying a subject in need of treatment comprises determining an increase of IFN α in the cerebrospinal fluid of the patient.
- 37. The method of any one of claims 35-36, wherein administering a therapeutically effective amount of B18R or a variant thereof and cART occurs simultaneously.
- 38. The method of any one of claims 35-37, wherein the subject with HAND has previously undergone cART treatment without administering B18R.
- 39. The method of any one of claims 35-38, wherein the cART comprises Atazanavir, Tenofovir, and Emtricitabine.
- 40. The method of any one of claims 35-39, wherein both the B18R or a variant thereof and cART are administered subcutaneously.
- 41. A method of improving the learning and memory function in a subject infected with HIV comprising
 - a. identifying a subject in need of treatment; and
 - b. administering a therapeutically effective amount of B18R or a variant thereof and cART.
- 42. The method of claim 41, wherein identifying a subject in need of treatment comprises determining an increase of IFN α in the cerebrospinal fluid of the patient.
- 43. The method of any one of claims 41-42, wherein administering a therapeutically effective amount of B18R or a variant thereof and cART occurs simultaneously.
- 44. The method of any one of claims 41-43, wherein the subject infected with HIV has previously undergone cART treatment without administering B18R.
- 45. The method of any one of claims 41-44, wherein the cART comprises Atazanavir, Tenofovir, and Emtricitabine.

46. The method of any one of claims 41-45, wherein both the B18R or a variant thereof and cART are administered subcutaneously.

47. The method of claims 6-4630, wherein the subject is a human.




FIG. 1A, FIG. 1B




FIG. 1C

Experimental Method




FIG. 2




FIG. 3A, FIG. 3B, FIG. 3C, FIG. 3D




FIG. 4A, FIG. 4B, FIG. 4C, FIG. 4D




FIG. 5





FIG. 6

8/10



C. AMPA Staining - Rat Neuronal Cultures




FIG. 7A, FIG. 7B, FIG. 7C




FIG. 8




FIG. 9A, FIG. 9B, FIG. 9C, FIG. 9D, FIG. 9E, FIG. 9F, FIG. 9G, FIG. 9H

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 18/55888

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(8) - A61K 38/21, C07K 14/555 (2018.01)
 CPC - A61K 38/1793, C07K 14/555, C07K 16/249, A61P 31/12, C12N 2740/16063

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History Document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History Document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History Document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ---	US 2006/0194212 A1 (SKURKOVICH et al.) 31 August 2006 (31.08.2006); abstract	1 ---
Y		2
Y	FRITZ-FRENCH et al. "The Recombinant Vaccinia Virus Gene Product, B18R, Neutralizes Interferon Alpha and Alleviates Histopathological Complication in an HIV Encephalitis Mouse Model" Journal of Interferon and Cytokine Research, 2014, Vol. 34, No. 7; abstract; Pg 516, col 1, para 2	2

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

18 December 2018

Date of mailing of the international search report

04 FEB 2019

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
 P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
 PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 18/55888

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 3-5, 9-10, 17, 21-22, 26-28, 32-34, 38-40, 44-47
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I: claims 1-2, drawn to a composition comprising an interferon-alpha (IFNalpha) binding protein and combined anti-retroviral therapy (cART).

Group II: claims 6-8, 11-16, 18-20, 23-25, 29-31, 35-37, 41-43, drawn to a method of treating a subject with HIV associated neurodegenerative disorder (HAND).

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

*****Continued in Supplemental Box*****

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-2

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 18/55888

Continuation of Box No. III (Observations where unity of invention is lacking):

Special Technical Features

Group I includes the special technical feature of a composition comprising an IFNalpha binding protein and cART, not required by Group II.

Group II includes the special technical feature of a method of treating a subject with HAND, not required by Group I.

Common Technical Features

The inventions of Groups I and II share the technical feature of an IFNalpha binding protein and cART.

However, these shared technical features do not represent a contribution over prior art in view of US 2006/0194212 A1 to Skurkovich et al. (hereinafter 'Skurkovich').

Skurkovich teaches (instant claim 1) a composition comprising an interferon-alpha (IFNalpha) binding protein and combined anti-retroviral therapy (cART) (Abstract- The invention includes methods of treating HIV infection in a patient where the method includes administration of an antibody to TNF-alpha and an antibody to interferon-gamma to the patient and administering antiretroviral therapy to a patient. The invention further includes methods of treating HIV infection in a patient where the method comprises administration of an antibody to TNF-alpha and an antibody to alpha interferon to the patient and administering antiretroviral therapy to a patient. The invention further includes a method of treating HIV infection in a patient where the method includes administering an antibody to alpha interferon and antiretroviral therapy to a patient. The invention further includes a method of treating an HIV infection in a patient where the method comprises administering a chimeric TNF-alpha receptor and anti-retroviral therapy to a patient.).

As said technical features were known in the art at the time of the invention, these cannot be considered special technical features that would otherwise unify the groups.

Groups I and II therefore lack unity under PCT Rule 13 because they do not share a same or corresponding special technical feature.

Note: Claims 3-5, 9-10, 17, 21-22, 26-28, 32-34, 38-40, 44-47 are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Note, Claim 47 which depends from "The method of claims 6-4630" is objected to. Claim 47 is reconstrued to "The method of claims 6-46".